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regulation	of	 lipogenesis	through	regulating	gene	expression	of	proteins	 involved	 in	fatty	acid	
biosynthesis.	In	GBM	and	many	other	cancer	types,	overexpression	of	SREBP-1	has	been	found	
to	be	associated	with	 its	aggressive	pathological	 features.	Therefore,	SREBPs	can	be	potential	
targets	 for	 therapeutic	 treatment	 in	 GBM.	 	 We	 hypothesize	 that	 Indip	 and	 other	 SREBP1	
inhibitors	such	as	PF429242	and	fatostatin	arrest	the	proliferation	of	cells	in	a	well-established	
model	of	GBM	cells,	the	T98G	cell	line,	maintained	in	vitro	in	culture.		
The	present	study	 investigates	the	efficacy	of	SREBP-1	 inhibitors	such	as	 fatostatin,	PF429242	











human pancreatic carcinoma (MIA PaCa-2) cells.	 Furthermore,	 the	 combination	 of	 Indip	
(indirect)	and	PF429242	(direct)	treatment	had	the	greatest	effect	on	promoting	apoptosis	(87%	
cell	death),	compared	to	single	drug	treatment	(40	%	by	Indip	alone	and	60%	by	PF429242).	These	
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viability,	 proliferation	 and	 migration	 rate	 when	 compared	 to	 the	 vehicle	 treated	 T98G	
glioblastoma	cells.		Fatostatin,	Indip	and	PF429242	arrested	the	cell	proliferation	at	G2/M	phase.	
They	 impeded	 cell	 migration	 through	 CDK-5	 inhibition	 and	 induced	 apoptosis	 by	 increasing	










Glioblastoma	multiforme	 (GBM)	 is	 the	most	 common	 and	 deadliest	malignant	 primary	 brain	
tumor	of	the	central	nervous	system	(CNS),	referred	to	as	glioma1,	2.	GBM	is	considered	to	be	a	
rare	 tumor	 affecting	 0.1%	 of	 the	 population	 with	 a	 survival	 rate	 of	 12-14	 months	 and	 its	
incidences	 increased	 up	 to	 3%	 per	 year2,	 3.	 GBM	 are	 classified	 as	 Grade	 IV	 (most	 serious)	
astrocytoma	 according	 to	 the	 World	 Health	 Organization	 (WHO)	 tumor	 classification	 and	
accounts	 for	 more	 than	 60%	 of	 all	 brain	 tumors	 in	 adults4.	 Current	 drug	 therapy	 like	
temozolomide	(TMZ)	increased	the	3-	and	5-year	survival	rate	to	16%	and	9.8%,	respectively5.	







cells,	 thus,	 enzymes	 involved	 in	 fatty	 acid	 metabolism	 have	 attracted	 major	 interest	 as	 a	
therapeutic	target	for	cancer	biology.	Studies	have	shown	that	inhibiting	fatty	acid	synthase	or	
lipogenesis	induces	cancer	cell	death10.	The	sterol	regulatory	element-binding	proteins	(SREBPs)	
have	gained	significant	 interest	as	a	possible	 therapeutic	 target	 for	cancer	 treatment.	SREBPs	
regulate	fatty	acid	and	cholesterol	biosynthesis11.	Elevated	lipid	biogenesis	in	GBM	is	regulated	
by	 lipid	 transcription	 factor	 sterol	 regulatory	 element-binding	 protein	 1	 (SREBP-1)12.	 In	many	











































and	 spread.	 The	 cells	were	 further	 incubated	with	media	 alone	or	with	 Indip	 (30-1,000	µM),	
















250	 µM	 Indip	 (INDIP)	 did	 not	 significantly	 prevent	 proliferation	 of	 T98G	 cells	 after	 4	 days	









To	 verify	 that	 fatostatin,	 PF429242	 and	 Indip	 inhibit	 SREBP-1	 activation	 and	 its	






































It	 has	 been	 shown	 in	 prostate	 cancer	 cells	 that	 fatostatin	 induces	 apoptosis	 through	 the	
activation	of	caspase-317.	We	therefore	investigated	whether	the	inhibition	of	SREBP-1	similarly	
induces	apoptosis	in	T98G	cells.	Cells	were	incubated	with	250	µM	Indip	(INDIP),	5	µM	fatostatin	











activity	 by	 2.9	 and	 3.7	 fold	 (p<0.001,	 n=3),	 respectively	 whereas	 Indip	 treatment	 had	 no	
significant	effect.	Therefore,	the	inhibition	of	SREBP-1	triggers	the	apoptotic	cascade	pathway	at	
least	in	part	by	caspase-3	activation	in	glioblastoma	cells.					
						2.1.4	 	 	 Treatment	 of	 T98G	 glioblastoma	 cells	 with	 SREBP-1	 inhibitors	 modulates	 cell	
morphology	and	inhibits	Multicellular	Tumor	Spheroids	(MCTS)	growth.		
It	has	been	shown	that	T98G	cells	are	a	hyperpentaploid	cell	line	with	irregularly	shaped	nuclei	







fatostatin	 significantly	 decreased	 the	 relative	 cell	 size	by	 35%	and	42%	 respectively	 (Fig.	 4b).	










analysis	 showed	 that	 at	 day	 7,	 fatostatin,	 PF429242	 and	 TMZ	 drug	 treatments	 had	 a	 similar	






MCST	(Fig.	4c-4d).	 	Taken	together	these	data	 indicate	that	 inhibition	of	SREBP-1	reduces	the	















in	 T98G	 cell	migration.	 Cyclin	 dependent	 kinases	 (CDK)	 are	well	 known	 to	 play	 a	 role	 in	 cell	
migration	 and	 have	 been	 identified	 to	 be	 involved	 in	 promoting	metastasis	 by	 reducing	 the	
activity	 of	 caldesmon20	 thus	making	 CDKs	 a	 target	 for	 glioblastoma	 therapy21.	 These	 studies	





























tumor	 cell	 death.	 	 This	was	 a	 5-fold	 increase	 compared	 to	 Indip	 alone	 and	 a	 3-fold	 increase	
compared	to	PF429242	alone	(Fig.	6c).	The	combinations	of	Indip/TMZ	and	Indip/fatostatin	were	











Figure.1	 Time	 and	 concentration-dependent	 effects	 of	 Indip,	 fatostatin,	 PF429242	 and	
Temozolamide	(TMZ)	on	percentage	(%)	cell	proliferation	in	T98G	cells.	
Indip,	Fatostatin,	PF429242	and	Temozolamide	inhibited	the	proliferation	of	T98G	cells	in	a	time-	










then	 incubated	 with	 anti-inulin	 receptor	 antibody,	 followed	 by	 incubating	 with	 Alexa	 Fluor	
conjugated	 secondary	antibody	 for	 fluorescent.	Dansyl	 Fluorophore	 labeled	 Indip	 is	 shown	 in	
blue	and	insulin	receptor	reference	in	green.	Images	were	taken	using	laser	scanning	microscopy	
with	 100X	 magnification.	 Each	 point	 represents	 mean	 ±	 SEM	 (n=3)	 values.	 The	 values	 were	











Western	 blot	 analysis	 of	 sterol	 regulatory	 element	 binding	 protein	 1	 (SREBP1)	 and	 its	
downstream	 signaling	 proteins	 on	 250	 µM	 Indip	 (INDIP),	 5	 µM	 Fatostatin	 (FAT)	 and	 10	 µM	




acid	 synthase,	 (c)	 Hydroxymethylglutaryl-CoA	 reductase	 (HMGCoAR),	 (d)	 Stearoyl-CoA	
desaturase	(SCD-1),	(e)	 Insulin	 induced	gene-1	(Insig-1).	Values	were	expressed	in	mean±SEM,	
n=3	and	similar	results	were	obtained	in	three	individual	experiments.	Mean	difference	between	















cells.	 Percentage	 of	 apoptotic	 cell	 death	 was	 measured	 at	 various	 time	 points	 using	 flow	
cytometry	 based	 PI-staining	 and	 quantitated	 by	 FloJo	 software.	 (f),	 Caspase-3	 activity	 was	
determined	by	western	blot.	5	µM	Fatostatin	(FAT)	and	10	µM	PF429242	(PF)	increased	active-
















of	 each	 T98G	 cell	 was	 measured	 by	 Phase-contrast	 microscopy	 at	 10x	 magnification	 after	
detaching	 the	 cells	with	 trypsin	 and	 2D	 surface	 area	 of	 cells	were	 quantified.	 (a),	 T98G	 cells	
images	produced	by	Phase-contrast	microscopy	after	72	hr	 incubation	 Indip,	 (b),	Quantitative	
41		
analysis	of	the	cell	size	after	 incubating	with	the	SREBP	inhibitors.	 Indip,	Fatostatin,	PF429242	
and	Temozolomide	 impeded	MCTS	 formation	and	growth	 in	T98G	cells.	 (c),	The	 formation	of	
MCTS	from	T98G	cells	after	7	and	14	days	incubation.	A	phase-contrast	microscopy	was	used	to	
monitor	 the	MCTS	 formation	 and	growth.	 (b),	 The	diameter	of	 each	MCTS	was	measured	by	
phase	contrast	microscopy	at	4X	magnification	and	2D	surface	area	of	MCTS	was	calculated.	T98G	
cells	were	cultured	in	EMEM	with	Matrigel	and	then	treated	with	250	µM	Indip	(INDIP),	5	µM	













of	 the	 cellular	 migration	 rate	 after	 72	 h.	 	 (c)	 The	 decrease	 in	 T98G	 migration	 was	 through	
inhibition	of	CDK-5.	Cells	were	treated	with	250	µM	Indip	(INDIP),	5	µM	Fatostatin	(FAT)	and	10	
µM	PF429242	 (PF)	 for	 48	h	 then	Western	blotted	 for	 CDK-5.	Untreated	 cells	were	 incubated	
without	 inhibitors	 (C).	 Values	 were	 expressed	 in	 mean±SEM,	 n=3	 and	 similar	 results	 were	







Fig.6.	 Treatment	 with	 Indip,	 fatostatin,	 PF429242	 and	 TMZ	 have	 an	 additive	 effect	 on	
suppressing		proliferation	of	T98G	cells.	




















(n=3)	 values.	 The	 values	 were	measured	 using	 one	 way	 Anova	 followed	 by	 tukey’s	 multiple	
46		
comparison	test	as	post	hoc	in	Graphpad	Prism		version	6.0.	**	and	#	indicates	P	value	<	0.01	and	

























5%CO2.	 After	 overnight	 attachment,	 the	 cells	 were	 treated	 with	 either	 vehicle	 (control),	
PF429242,	Indip	or	fatostatin	for	48	hours.	The	concentrations	of	fatostatin,	Indip	and	PF429242	




















Cells	were	washed	 in	 ice	 cold	PBS	X	2	 times	and	 then	 incubated	 in	 staining	buffer	 (60	μg/ml	





performed	 by	 adding	 120	 µl/well	 of	 Matrigel	 (Sigma,	 E1270),	 then	 spreading	 evenly	 on	 the	








were	 imaged	 on	 a	 phase	 contrast	 microscopy	 (OLYMPUS,	 IX71)	 at	 4X	 magnification.	 Tumor	
sphere	size	was	analyzed	using	ImageJ	software.			
2.3.6		Scratch	Assay.	







a	 4x	 objective	 lens.	 The	 relative	 distance	 traveled	 by	 the	 cells	 into	 the	 acellular	 region	 was	
determined	using	ImageJ	software.	Cells	treated	with	diluent	were	used	as	a	baseline	control.	
2.3.7	 	 Immunofluorescence	 staining	 and	 Fluorescence	 Studies	 of	 Labeled	 Indip	 Containing	
Dansyl	Fluorophore.		
Immunostaining	 was	 adopted	 from	 Abcam	 protocol.	 Briefly,	 coverslips	 were	 coated	 with	
polyethylineimine	 for	 5	 min	 at	 room	 temperature.	 Then	 T98G	 cells	 were	 cultured	 on	 glass	

























rotator	 an	 shaken	 at	 240	 rpms	 overnight	 at	 37ºC	 and	 5%	 CO2	 to	 remove	 oligodendrocyte	






	All	 the	 statistical	 analyses	 were	 conducted	 using	 Graphpad	 Prism	 	 6	 software	 (GraphPad	
Software,	 San	Diego,	 CA).	 Kaplan-Meyer	 survival	 curves	were	 compiled	 using	 Prism	 software	
(GraphPad).	Tumor	sphere	size,	cell	cycle,	proliferation	and	cell	migration	were	compared	by	one-
way	 ANOVA	 test.	 Additional	 experiments	 were	 analyzed	 by	 the	 unpaired	 t-test.	 Data	 are	
presented	as	mean	±	standard	deviation	(SD).	P	<	0.05	was	considered	statistically	significant.	
DISCUSSION		







SREBP-1	regulates	fatty	acid	biosynthesis.	Insig-1 levels raise with the addition of Indip and 
subsequent inhibition of the activation of the SREBP-1 lipid transcription factor as the 














carcinogenesis,	 cell	 proliferation	 and	 apoptosis26,27.	 Furthermore,	 inhibition	 of	 SREBP-1	
significantly	 down-regulated	 fatty	 acid	 synthase	 and	 SCD-1	 levels,	 indicating	 that	 SREBP-1	
inhibition	 regulates	 cancer-associated	 fatty	 acid	metabolism,	 thus	 inhibiting	 GBM	 cancer	 cell	
growth.	 Cancer	 cells	 including	 T98G	 cells	 have	 active	 signaling	 networks	 to	 meet	 their	 high	
demand	 for	 cholesterol28.	 Overexpression	 of	 HMGCoAR	 is	 involved	 in	 the	 global	 metabolic	
transformation	of	cancer	cells	and	high	levels	of	cholesterol	may	negatively	affect	the	outcome	

















fatty	 acid	 synthesis,	 as	well	 as	HMGCoAR,	 a	 key	 regulator	of	mevolonate	pathway	which	 are	
involved	in	the	global	metabolic	tumorigenicity	of	cancer	cells	including	GBM.	SREBP-1	has	been	
found	 to	 be	 up-regulated	 in	 GBM,	 making	 it	 a	 putative	 target.	 The	 data	 presented	 herein	













Drugs		 Indip	 FATOSTATIN	 PF429242	 TMZ	
IC50	 of	
24hr(μM)	
250	 5	 10	 500	
IC50	of	48hr	
(μM)	
155	 2.64	 5.5	 334.3	
IC50	of	72hr	
(μM)	
192.4	 1.98	 3.9	 273.2	
	
Table	2	
Drugs		 Indip	 FATOSTATIN	 PF429242	 TMZ	
IC50	 of	
24hr(μM)	







N/A	 17.4	 19	 438.4	
IC50	of	72hr	
(μM)	

















G	 and	 National	 Cancer	 Institute	 of	 Canada	 Clinical	 Trials	 G.	 Effects	 of	 radiotherapy	 with	
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